Literature DB >> 31900291

Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease.

Silvia Sookoian1,2, Adrian Salatino3,4, Gustavo Osvaldo Castaño5, Maria Silvia Landa3,4, Cinthia Fijalkowky3,4, Martin Garaycoechea6, Carlos Jose Pirola1,4.   

Abstract

OBJECTIVE: We aimed to characterise the liver tissue bacterial metataxonomic signature in two independent cohorts of patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD) diagnosis, as differences in the host phenotypic features-from moderate to severe obesity-may be associated with significant changes in the microbial DNA profile. DESIGN AND METHODS: Liver tissue samples from 116 individuals, comprising of 47 NAFLD overweight or moderately obese patients, 50 NAFLD morbidly obese patients elected for bariatric surgery and 19 controls, were analysed using high-throughput 16S rRNA gene sequencing.
RESULTS: Liver bacterial DNA profile significantly differs between morbidly obese and non-morbidly obese patients with NAFLD. Bacteroidetes (p=1.8e-18) and Firmicutes (p=0.0044) were over-represented in morbidly obese patients and Proteobacteria (p=5.2e-10)-specifically Gammaproteobacteria and Alphaproteobacteria, and Deinococcus-Thermus (p=0.00012)-were over-represented in the non-morbidly obese cohort. Cohort-specific analysis of liver microbial DNA signatures shows patterns linked to obesity. The imbalance in Proteobacteria (Alpha or Gamma) among non-morbidly obese patients, and Peptostreptococcaceae, Verrucomicrobia, Actinobacteria and Gamma Proteobacteria DNA among morbidly obese patients was associated with histological severity. Decreased amounts of bacterial DNA from the Lachnospiraceae family were associated with more severe histological features. Proteobacteria DNA was consistently associated with lobular and portal inflammation scores. Microbial DNA composition corresponded to predicted functional differences.
CONCLUSION: This is the first comprehensive study showing that the liver tissue of NAFLD patients contains a diverse repertoire of bacterial DNA (up to 2.5×104 read counts). The liver metataxonomic signature may explain differences in the NAFLD pathogenic mechanisms as well as physiological functions of the host. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  fatty liver; intestinal microbiology; liver biopsy; nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2020        PMID: 31900291     DOI: 10.1136/gutjnl-2019-318811

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  CX3CR1 regulates gut microbiota and metabolism. A risk factor of type 2 diabetes.

Authors:  Celine Pomié; Florence Servant; Lucile Garidou; Vincent Azalbert; Aurélie Waget; Pascale Klopp; Céline Garret; Julie Charpentier; Francois Briand; Thierry Sulpice; Benjamin Lelouvier; Victorine Douin-Echinard; Rémy Burcelin
Journal:  Acta Diabetol       Date:  2021-03-22       Impact factor: 4.280

Review 2.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Authors:  Herbert Tilg; Timon E Adolph; Michael Dudek; Percy Knolle
Journal:  Nat Metab       Date:  2021-12-20

3.  Neonatal Exposure to BPA, BDE-99, and PCB Produces Persistent Changes in Hepatic Transcriptome Associated With Gut Dysbiosis in Adult Mouse Livers.

Authors:  Joe Jongpyo Lim; Moumita Dutta; Joseph L Dempsey; Hans-Joachim Lehmler; James MacDonald; Theo Bammler; Cheryl Walker; Terrance J Kavanagh; Haiwei Gu; Sridhar Mani; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2021-10-27       Impact factor: 4.109

4.  Intestinal Microbiota Participates in the Protective Effect of HO-1/BMMSCs on Liver Transplantation With Steatotic Liver Grafts in Rats.

Authors:  Mengshu Yuan; Ling Lin; Huan Cao; Weiping Zheng; Longlong Wu; Huaiwen Zuo; Xiaorong Tian; Hongli Song
Journal:  Front Microbiol       Date:  2022-06-10       Impact factor: 6.064

Review 5.  Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

Review 6.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

Review 7.  Emerging concepts in intestinal immune control of obesity-related metabolic disease.

Authors:  Saad Khan; Helen Luck; Shawn Winer; Daniel A Winer
Journal:  Nat Commun       Date:  2021-05-10       Impact factor: 14.919

8.  CRIg+ Macrophages Prevent Gut Microbial DNA-Containing Extracellular Vesicle-Induced Tissue Inflammation and Insulin Resistance.

Authors:  Zhenlong Luo; Yudong Ji; Hong Gao; Felipe Castellani Gomes Dos Reis; Gautam Bandyopadhyay; Zhongmou Jin; Crystal Ly; Ya-Ju Chang; Dinghong Zhang; Deepak Kumar; Wei Ying
Journal:  Gastroenterology       Date:  2020-11-02       Impact factor: 22.682

Review 9.  Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review.

Authors:  Jacqueline Hoozemans; Maurits de Brauw; Max Nieuwdorp; Victor Gerdes
Journal:  Metabolites       Date:  2021-05-31

10.  Hepatic microbiome in healthy lean and obese humans.

Authors:  Malte Palm Suppli; Jonatan Ising Bagger; Benjamin Lelouvier; Amandine Broha; Mia Demant; Merete Juhl Kønig; Charlotte Strandberg; Asger Lund; Tina Vilsbøll; Filip Krag Knop
Journal:  JHEP Rep       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.